To assess systematically the clinical effectiveness and cost-effectiveness of sibutramine in the management of obesity.
A narrative synthesis was performed, organised according to study end point and type of weight-management programme (weight loss or weight maintenance). Statistical pooling was performed where the groups of trials were considered to be of sufficient similarity. For continuous outcomes, the studies were pooled using the weighted mean difference (WMD). For dichotomous outcomes, the relative risks with 95% confidence intervals (CIs) were calculated. Random-effects models were used for all analyses.
How were differences between studies investigated?
Heterogeneity was assessed in all analyses using the chi-squared statistic; heterogeneity was considered to be present when the associated P-value was less than 0.10.
Results of the review
Sixteen RCTs were included in the review. In addition, one economic evaluation was also included in the analysis.
The methodological quality of the included trials was judged to be moderate to good.
The majority of the placebo-controlled trials and pooled estimates suggested that sibutramine produced a statisticallysignificant greater weight loss than placebo at all of the observed end points. The WMD for weight change at 8 weeks (3 trials) was -3.4 kg (95% CI : -4.22, 2.58, P<0.00001). The mean difference for weight change ranged from -4.0 to 9.1 kg at 6 months, and from -4.1 to 4.8 kg at one year.
The most frequent dosing regimen was 10 to 20 mg/day. The findings suggested a dose-effect relationship in terms of weight loss. Sibutramine was also associated with better weight maintenance relative to placebo; the difference was statistically significant.
Results from mainly small trials showed that sibutramine produced more favourable outcomes in terms of loss of fat mass, reduction in body mass index, and losses of at least 5 and 10% of initial body weight.
Between-group differences for waist circumference, hip circumference, and waist-hip ratio did not reach statistical significance.
Similar results for weight loss were found in trials recruiting only participants with type 2 diabetes; between-group differences for changes in indicators of glycaemic control were not usually statistically significant.
Sibutramine use was associated with small, statistically-significant increases in pulse rate, heart rate and blood-pressure.
Eleven participants in the sibutramine 15-mg group and 5 in the placebo group withdrew due to adverse events.
Cost information
The review reported that the cost per quality-adjusted life-year was £10,500.
